Concentration:	1 mg / ml, determined by the Lowry method
Source:	From fresh human plasma that has tested negative for Hepatitis C, HIV-I and HIV-II antibodies as well as Hepatitis surface antigens.
Purification:	After series ultracentrifugations, High Density Lipoprotein (HDL) is isolated from human plasma. Apo AI is purified from delipidated HDL, followed by gel-filtration.
Purity:	≥ 98% by SDS-PAGE
Buffer:	20 mM Tris-HCl, 140 mM NaCl, 0.02% NaN3, 0.5 mM EDTA, pH 7.4.
Storage:	-20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.

 

Importance

Apo AI comprises approximately 70% of the protein moiety in HDL. It is a single polypeptide chain consisting of 243 amino acid residues without disulfide bound and with glutamic acid as the C-terminal residue and aspartic acid as the N-terminal residue. The molecular weight is reported to be 28 kDa (Brewer et al., 1978).

The roles of Apo AI in HDL function include reverse cholesterol transportation, lipid cholesterol binding, lecithin-cholesterol acyl transferase (LCAT) activation, and receptor binding, which is responsible for cholesterol esterification in plasma. Besides participate in cholesterol metabolism, Apo AI and HDL also suppress neutrophil activation, inhibit bacterial endotoxin, induce trypanosomal lysis, and other physiological activities. (Brouillette et al., 2001)

Apo AI levels may be inversely related to the risk of coronary disease. In previous research, Apo AI may affect diet-induced inflammation by either directly or indirectly altering lipid rafts. (Cheng et al., 2012)

Brewer, H. B., T. Fairwell, A. LaRue, R. Ronan, A. Houser, and T. J. Bronzert. “The amino acid sequence of human Apoa-I, an apolipoprotein isolated from high density lipoproteins.” Biochemical and Biophysical Research Communications 80.3 (1978): 623-30.

Brouillette, Christie G., G.m. Anantharamaiah, Jeffrey A. Engler, and David W. Borhani. "Structural Models of Human Apolipoprotein A-I: A Critical Analysis and Review." Biochimica Et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids (2001): 4-46.

Cheng, Andrew M., Priya Handa, Sanshiro Tateya, Jay Schwartz, Chongren Tang, Poulami Mitra, John F. Oram, Alan Chait, and Francis Kim. "Apolipoprotein A-I Attenuates Palmitate-Mediated NF-κB Activation by Reducing Toll-Like Receptor-4 Recruitment into Lipid Rafts." PLoS ONE 7.3 (2012): e33917.

 

Citations

[P03][P04]	2020	Stamatikos, Alexis; Knight, Ethan; Vojtech, Lucia; Bi, Lianxiang; Wacker, Bradley K.; Tang, Chongren; Dichek, David A. (2020): Exosome-Mediated Transfer of Anti-miR-33a-5p from Transduced Endothelial Cells Enhances Macrophage and Vascular Smooth Muscle Cell Cholesterol Efflux. Human Gene Therapy 31 (3-4), pp. 219–232. DOI: 10.1089/hum.2019.245.
[P03][P04]	2019	Hsu, Yun-Hsun; Toh, Jia-Jia; Chang, Chiz-Tzung; Liu, Mine-Yine (2019): Investigating apolipoproteins of human high-density lipoprotein by cyclodextrin-micellar electrokinetic chromatography. Journal of Chromatography. A 1593, pp. 164–173. DOI: 10.1016/j.chroma.2019.01.073.
[P03][P04]	2018	Woller, Sarah A.; Choi, Soo-Ho; An, Eun Jung; Low, Hann; Schneider, Dina A.; Ramachandran, Roshni et al. (2018): Inhibition of Neuroinflammation by AIBP: Spinal Effects upon Facilitated Pain States. In Cell reports 23 (9), pp. 2667–2677. DOI: 10.1016/j.celrep.2018.04.110.
[P03][P04]	2016	Han, Chang Yeop; Tang, Chongren; Guevara, Myriam E.; Wei, Hao; Wietecha, Tomasz; Shao, Baohai et al. (2016): Serum amyloid A impairs the antiinflammatory properties of HDL. In The Journal of clinical investigation 126 (1), pp. 266–281. DOI: 10.1172/JCI83475.
[P03][P04]	2016	Yassine, Hussein N.; Feng, Qingru; Chiang, Jiarong; Petrosspour, Larissa M.; Fonteh, Alfred N.; Chui, Helena C.; Harrington, Michael G. (2016): ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer"s Disease. In Journal of the American Heart Association 5 (2). DOI: 10.1161/JAHA.115.002886.
[P03][P04]	2015	Zhang, Hongming; Li, Xiaoyan; Qian, Zongjie (2015): Regulation of macrophage cholesterol efflux and liver X receptor α activation by nicotine. In International journal of clinical and experimental medicine 8 (9), pp. 16374–16378.
[P03][P04]	2014	Braesch-Andersen, Sten; Beckman, Lena; Paulie, Staffan; Kumagai-Braesch, Makiko (2014): ApoD mediates binding of HDL to LDL and to growing T24 carcinoma. In PLoS ONE 9 (12), e115180. DOI: 10.1371/journal.pone.0115180.
[P03][P04]	2014	Talayero, Beatriz; Wang, Liyun; Furtado, Jeremy; Carey, Vincent J.; Bray, George A.; Sacks, Frank M. (2014): Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease. In J. Lipid Res. 55 (10), pp. 2167–2177. DOI: 10.1194/jlr.M042333.
[P03][P04]	2013	Hibert, Pierre; Prunier-Mirebeau, Delphine; Beseme, Olivia; Chwastyniak, Maggy; Tamareille, Sophie; Lamon, Delphine et al. (2013): Apolipoprotein a-I is a potential mediator of remote ischemic preconditioning. In PLoS ONE 8 (10), e77211. DOI: 10.1371/journal.pone.0077211.
[P03][P04]	2013	Umemoto, Tomio; Han, Chang Yeop; Mitra, Poulami; Averill, Michelle M.; Tang, Chongren; Goodspeed, Leela et al. (2013): Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. In Circulation research 112 (10), pp. 1345–1354. DOI: 10.1161/CIRCRESAHA.111.300581.
[P03][P04]	2012	Cheng, Andrew M.; Handa, Priya; Tateya, Sanshiro; Schwartz, Jay; Tang, Chongren; Mitra, Poulami et al. (2012): Apolipoprotein A-I Attenuates Palmitate-Mediated NF-κB Activation by Reducing Toll-Like Receptor-4 Recruitment into Lipid Rafts. In PLoS ONE 7 (3), e33917. DOI: 10.1371/journal.pone.0033917.
[P03][P04]	2011	Borges, Chad R.; Oran, Paul E.; Buddi, Sai; Jarvis, Jason W.; Schaab, Matthew R.; Rehder, Douglas S. et al. (2011): Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity. In Clinical chemistry 57 (5), pp. 719–728. DOI: 10.1373/clinchem.2010.156976.
[P03][P04]	2011	Wang, Yanan; Berbée, Jimmy F. P.; Stroes, Erik S.; Smit, Johannes W. A.; Havekes, Louis M.; Romijn, Johannes A.; Rensen, Patrick C. N. (2011): CETP expression reverses the reconstituted HDL-induced increase in VLDL. In J. Lipid Res. 52 (8), pp. 1533–1541. DOI: 10.1194/jlr.M016659.
[P03][P04]	2009	Hongo, Shigeki; Watanabe, Takuya; Arita, Shigeko; Kanome, Tomoko; Kageyama, Haruaki; Shioda, Seiji; Miyazaki, Akira (2009): Leptin modulates ACAT1 expression and cholesterol efflux from human macrophages. In American Journal of Physiology-Endocrinology and Metabolism 297 (2), E474-82. DOI: 10.1152/ajpendo.90369.2008.
[P03][P04]	2009	Vries-van der Weij, Jitske de; Haan, Willeke de; Hu, Lihui; Kuif, Maarten; Oei, H. Ling D. W.; van der Hoorn, José W. A. et al. (2009): Bexarotene Induces Dyslipidemia by Increased Very Low-Density Lipoprotein Production and Cholesteryl Ester Transfer Protein-Mediated Reduction of High-Density Lipoprotein. In Endocrinology 150 (5), pp. 2368–2375. DOI: 10.1210/en.2008-1540.
[P03][P04]	2008	Troutt, Jason S.; Alborn, William E.; Mosior, Marian K.; Dai, Jiannong; Murphy, Anthony T.; Beyer, Thomas P. et al. (2008): An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma. In J. Lipid Res. 49 (3), pp. 581–587. DOI: 10.1194/jlr.M700385-JLR200.
[P03][P04]	2007	Nagalla, Srinivasa R.; Canick, Jacob A.; Jacob, Thomas; Schneider, Kimberly A.; Reddy, Ashok P.; Thomas, Archana et al. (2007): Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers. In J. Proteome Res. 6 (4), pp. 1245–1257. DOI: 10.1021/pr060539h.
[P03][P04]	2006	Yokoyama, Yuichiro; Kuramitsu, Yasuhiro; Takashima, Motonari; Iizuka, Norio; Terai, Shuji; Oka, Masaaki et al. (2006): Protein level of apolipoprotein E increased in human hepatocellular carcinoma. In International journal of oncology 28 (3), pp. 625–631.
[P03][P04]	2005	Lee, Ching Yin; Lesimple, Alain; Larsen, Asmund; Mamer, Orval; Genest, Jacques (2005): ESI-MS quantitation of increased sphingomyelin in Niemann-Pick disease type B HDL. In J. Lipid Res. 46 (6), pp. 1213–1228. DOI: 10.1194/jlr.M500011-JLR200.
[P03][P04]	2003	Lee, Ching Yin; Krimbou, Larbi; Vincent, Jérôme; Bernard, Chantal; Larramée, Pierre; Genest, Jacques; Marcil, Michel (2003): Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1) gene is associated with low HDL cholesterol. In Human genetics 112 (5-6), pp. 552–562. DOI: 10.1007/s00439-002-0893-1.
[P03][P04]	2003	Sniderman, Allan D.; Zhang, ZuJun; Genest, Jacques; Cianflone, Katherine (2003): Effects on apoB-100 secretion and bile acid synthesis by redirecting cholesterol efflux from HepG2 cells. In J. Lipid Res. 44 (3), pp. 527–532. DOI: 10.1194/jlr.M200187-JLR200.
[P03][P04]	2002	Rong, Rong; Ramachandran, Sumathi; Penumetcha, Meera; Khan, Nadya; Parthasarathy, Sampath (2002): Dietary oxidized fatty acids may enhance intestinal apolipoprotein A-I production. In J. Lipid Res. 43 (4), pp. 557–564.

academy biomed[A05]绵羊抗人类载脂蛋白AII多克隆抗体12A-S1a学院生物医学公司$ 155.00$ 155.00目录号数量1寄主物种： 羊浓度： 1毫克/毫升（OD 1.35 / 280 nm）抗原： 人类载脂蛋白AII纯化： 亲和纯化缓冲： 75 mM磷酸钠，75 mM NaCl，0.5 mM EDTA，0.02％NaN3，pH 7.2特异性 与人载脂蛋白AII特异性结合。免疫印迹和ELISA的稀释范围：1,000至80,000。用： 该抗体可用于检测血浆和脂蛋白中的载脂蛋白AII，免疫测定，免疫印迹，酶结合或生物素化。存储： -20°C长期保存，4°C短期保存。等分试样，以避免反复冻结和解冻。 *这些产品仅用于研究或制造用途，不能用于人体治疗或诊断应用。 重要性Apo AII占HDL的25％。它在人血浆中以77条氨基酸残基的2条相同链的二聚体形式存在，并通过二硫键连接。据报道，单链的分子量为8.7kDa（Brewer等，1972）。对小鼠的研究报道，apoAII可能具有促动脉粥样硬化作用（Warden等，1993）。然而，一项大型的欧洲前瞻性研究中的病例对照研究表明，血浆Apo AII浓度与冠心病事件密切相关（Birjmohun等，2007）。Birjmohun，RS，GM Dallinga-Thie，JA Kuivenhoven，ESg Stroes，JD Otvos，NJ Wareham，R.Luben，JJp Kastelein，K.-T. Khaw和SM Boekholdt。“载脂蛋白A-II与未来冠状动脉疾病的风险成反比。” 循环116（2007）：2029-035。Brewer，HB，SE Lux，R.Ronan和KM John。“人ApoLp-Gln-II（apoA-II），一种从高密度脂蛋白复合物中分离的载脂蛋白的氨基酸序列。” 美国国家科学院院刊69.5（1972）：1304-308。Warden，C.，C.Hedrick，J.Qiao，L.Castellani和A.Lusis。“过表达载脂蛋白A-II的转基因小鼠中的动脉粥样硬化。” 科学261（1993）：469-72。